-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On May 11, Hongri Pharmaceutical announced that the company's drug fasudil hydrochloride injection passed the quality and efficacy consistency evaluation of generic drugs.
It is understood that fasudil hydrochloride and its injection were jointly developed by Japan’s Asahi Kasei and Nagoya University.
In 2004, Asahi Kasei expanded fasudil hydrochloride to treat cerebral thrombosis in Japan for the treatment of acute cerebral thrombosis (within 48 hours after onset).
According to the "Chinese Guidelines for the Diagnosis and Treatment of Subarachnoid Hemorrhage 2019", subarachnoid hemorrhage (SAH) refers to a type of stroke in which blood flows into the subarachnoid space after a blood vessel ruptures at the bottom of the brain or on the surface of the brain, causing corresponding clinical symptoms, accounting for all 5% to 10% of strokes.
